Immunotherapy in triple-negative breast cancer: the role of immune checkpoint inhibitors

• Autor(a) principal: Branco, Susana
• Data de Publicação: 2022
• Outros Autores: Graça, Maria Inês, Morais, Sara
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.21/16171
• topic: Triple-negative breast cancer; TNBC; Immune checkpoint inhibitors; ICIs; PD-L1; PD-1; CTLA-4; Cancro de mama triplo-negativo; Inibidores de checkpoint imunológico

ABSTRACT - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, associated with a poor prognosis in both early and advanced stages. Chemotherapy remains the standard treatment for these patients, despite its limited benefit. Due to the disease’s aggressive features and lack of targeted therapies, several attempts have been made to disclose novel molecular targets. TNBC is now known to be an immunogenic breast cancer subtype. Therefore, immunotherapy has emerged as a promising treatment option for this disease. During the last few years, immune checkpoint inhibitors (anti-PD1/PD-L1 and anti-CTLA-4 monoclonal antibodies) have been investigated either as monotherapy or combined with conventional therapy in TNBC. Herein, we review the status of immunotherapy in TNBC, focusing on the value of immune checkpoint inhibitors.